Medical News Today -- St. Jude Medical, Inc. (NYSE:STJ) today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms. The company announced Australian Therapeutic Goods Administration (TGA) approval of the Current™ Accel implantable cardioverter defibrillator (ICD), the AnalyST™ Accel ICD and the Promote™ Accel cardiac resynchronization therapy defibrillator (CRT-D); the Durata™ high-voltage cardiac lead; and its SJM Confirm™ implantable cardiac monitor.
